<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00549263</url>
  </required_header>
  <id_info>
    <org_study_id>AVR110549</org_study_id>
    <nct_id>NCT00549263</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of SB797620 in Healthy Japanese Volunteers</brief_title>
  <official_title>A Bioequivalence Study With a Combination Tablet Formulation of Rosiglitazone (RSG) and Glimepiride (GLIM)(4mg/2mg) Compared to Concomitant Dosing of RSG 4mg Tablet and GLIM 1mg Commercial Tablet x 2 (4mg+2mg) in Japanese Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test whether the Drug levels in plasma after combination formulation tablet&#xD;
      dosing (SB797620) and separate formulation tablets dosing (rosiglitazone and glimepiride) to&#xD;
      Japanese Healthy volunteer would be the same or not.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No subjects enrolled, bio equivalence study, canceled before active.&#xD;
  </why_stopped>
  <start_date>February 2008</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Drug levels on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical laboratory test on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vital signs and 12-lead ECG on Day 1</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy Subjects</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB797620</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy subjects&#xD;
&#xD;
          -  They are Japanese males.&#xD;
&#xD;
          -  Aged 20 to 55 years, inclusive.&#xD;
&#xD;
          -  They have body mass index at screening within 18.5-25.0. Body weight 50-80kg.&#xD;
&#xD;
          -  AST(GOT), ALT(GPT), gumma-GPT and ALP: below the upper normal range&#xD;
&#xD;
          -  They are capable of giving written informed consent, which includes compliance with&#xD;
             the requirements and restrictions listed in the consent form.&#xD;
&#xD;
          -  They could refrain from smoking during hospitalization.&#xD;
&#xD;
          -  They are able to attend all visits and complete the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has any clinically relevant abnormality on medical examination, vital&#xD;
             sign, clinical laboratory test or medical history at screening in the medical opinion&#xD;
             of the investigator or the subject has a medical history that is not considered as&#xD;
             eligible for inclusion in this study by the investigator.&#xD;
&#xD;
          -  Known hepatic or biliary abnormalities such as Gilbert's syndrome.&#xD;
&#xD;
          -  Use of insulin or oral anti-hyperglycemic agents within the past 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  Subjects who have a history of lactose intolerance.&#xD;
&#xD;
          -  The subject has an allergy for any drug or idiosyncrasy. This excludes a pollen&#xD;
             allergy without current symptoms.&#xD;
&#xD;
          -  The subject is currently participating in another clinical study or post-marketing&#xD;
             study in which the subject is or will be exposed to an investigational or a&#xD;
             non-investigational drug or device.&#xD;
&#xD;
          -  The subject has participated in a clinical study with an investigational or a&#xD;
             non-investigational drug or device during the previous 4 months.&#xD;
&#xD;
          -  The subject has a screening ECG with a QTc value outside the range 320 to 450msec, a&#xD;
             PR interval of &gt;230msec and/or a QRS interval of &gt;120msec.&#xD;
&#xD;
          -  The subject has a heart rate outside the range 40 to 110 bpm at screening.&#xD;
&#xD;
          -  The subject has donated a unit of blood &quot;&gt;400mL&quot; within the previous 4 months or&#xD;
             &quot;&gt;200mL&quot; within the previous 1 month.&#xD;
&#xD;
          -  The subject is currently taking regular (or a course of) medication (including&#xD;
             prescribed drug, over-the-counter medication and herbal remedies), and can not cease&#xD;
             them 30 days prior to th first study drug dosing.&#xD;
&#xD;
          -  The subject has a history or current conditions of drug abuse or alcoholism.&#xD;
&#xD;
          -  History of alcohol consumption in the past six months exceeding 7 drinks per week&#xD;
             (where 1 drink is 350mL in terms of beer)&#xD;
&#xD;
          -  The subject is positive for syphilis, HBs antigen, HCV antibody, HIV antigen/antibody,&#xD;
             HTLV-1 antibody.&#xD;
&#xD;
          -  The subject is positive for urine drug screening.&#xD;
&#xD;
          -  Current history of hypo- or hyperglycemia as indicated by serum glucose values below&#xD;
             the laboratory-specified reference range or =110 mg/dL, at screening, or as reported&#xD;
             by the subject.&#xD;
&#xD;
          -  History of surgical procedures that might affect the absorption of RSG or GLIM (e.g.,&#xD;
             partial/total gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of hypersensitivity to thiazolidinediones, sulfonylureas or compounds with&#xD;
             similar chemical structures.&#xD;
&#xD;
          -  History of sensitivity to heparin, heparin-induced thrombocytopenia or sensitivity to&#xD;
             any of the study medications or components thereof.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <removed_countries>
    <country>Japan</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>October 23, 2007</study_first_submitted>
  <study_first_submitted_qc>October 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2007</study_first_posted>
  <last_update_submitted>February 19, 2015</last_update_submitted>
  <last_update_submitted_qc>February 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Bioequivalence</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

